# Zoetis Inc., et al.; Withdrawal of Approval of New Animal Drug Applications for Combination Drug Medicated Feeds Containing an Arsenical Drug
> **Food and Drug Administration** · Final rule; technical amendments. · Published 2014-02-27 · Effective 2014-03-10 · 79 FR 10976
## Document
- **Document number:** 2014-02617
- **Category:** other
- **Sub-agency:** Food and Drug Administration
- **Federal Register citation:** 79 FR 10976
- **CFR reference:** 21 CFR 556
- **Publication date:** 2014-02-27
- **Effective date:** 2014-03-10
- **HHS docket:** Docket No. FDA-2014-N-0002
## Abstract

The Food and Drug Administration (FDA) is amending the animal drug regulations to reflect the withdrawal of approval of 69 new animal drug applications (NADAs) and 22 abbreviated new animal drug applications (ANADAs) for use of arsanilic acid, carbarsone, or roxarsone Type A medicated articles to manufacture combination drug Type B and Type C medicated feeds. This action is being taken at the sponsor's request because the products are no longer manufactured or marketed. FDA is also amending the animal drug regulations to remove entries describing conditions of use for combination drug medicated feeds for which no NADA is approved. This action is being taken to improve the accuracy of the regulations.

## Source
- [Federal Register document](https://www.federalregister.gov/documents/2014/02/27/2014-02617/zoetis-inc-et-al-withdrawal-of-approval-of-new-animal-drug-applications-for-combination-drug)
---
*AI Analytics · CC0 1.0*